Expert Review of Cardiovascular Therapy最新文献

TAVI in low‑risk severe aortic stenosis: evidence, controversies and lifetime treatment strategy. TAVI治疗低风险重度主动脉瓣狭窄：证据、争议和终身治疗策略

IF 2.5

Expert Review of Cardiovascular Therapy Pub Date : 2026-09-04 DOI: 10.1080/14779072.2026.2729316

Kelly Wright, Arafat Rahman, Georgia Penny, Maneesha Mohanarajan, Angela Sara Philip, Amer Harky

{"title":"TAVI in low‑risk severe aortic stenosis: evidence, controversies and lifetime treatment strategy.","authors":"Kelly Wright, Arafat Rahman, Georgia Penny, Maneesha Mohanarajan, Angela Sara Philip, Amer Harky","doi":"10.1080/14779072.2026.2729316","DOIUrl":"https://doi.org/10.1080/14779072.2026.2729316","url":null,"abstract":"Transcatheter aortic valve implantation (TAVI) has expanded from a treatment for inoperable and high-risk aortic stenosis (AS) to an established therapeutic option for selected patients at low surgical risk; this review focuses on the outcomes of major trials comparing TAVI to traditional surgical aortic valve replacement (SAVR), highlighting outcomes and potential complications when considering lifetime valve management when moving into the younger population. A literature search of PubMed using terms such as 'transcatheter aortic valve replacement' and 'low surgical risk' were used to identify relevant publications from within the last 10 years. Recent randomized trials and follow-up studies suggest that, in appropriately selected low-risk patients, TAVI and SAVR provide broadly comparable mid-term outcomes for cardiovascular mortality, stroke and valve reintervention. However, important differences remain. TAVI is consistently associated with lower rates of new-onset atrial fibrillation but higher rates of permanent pacemaker implantation and paravalvular aortic regurgitation. As TAVI moves into younger and asymptomatic populations, unresolved questions remain around valve durability, coronary access, redo strategies and lifetime valve management, highlighting the central role of multidisciplinary heart-team assessment in selecting the optimal lifetime therapeutic strategy.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148891272","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Personalizing myocardial revascularization strategies in the setting of acute myocardial infarction. 急性心肌梗死的个体化心肌血运重建策略。

IF 2.5

Expert Review of Cardiovascular Therapy Pub Date : 2026-08-29 DOI: 10.1080/14779072.2026.2726771

Abhyuday Mandala, Lavinia Gabara, Nick Curzen, Richard J Jabbour

{"title":"Personalizing myocardial revascularization strategies in the setting of acute myocardial infarction.","authors":"Abhyuday Mandala, Lavinia Gabara, Nick Curzen, Richard J Jabbour","doi":"10.1080/14779072.2026.2726771","DOIUrl":"https://doi.org/10.1080/14779072.2026.2726771","url":null,"abstract":"Introduction: Revascularization post myocardial infarction is a complex interplay of patient and anatomical factors. There are a growing number of interventional tools providing both physiological and anatomical delineation of disease burden which can help determine method and extent of revascularization. A tailored approach is required taking into consideration shared decision making, co-morbidities and evolving treatment options.Areas covered: This review article explores the wide array of revascularization techniques of both the culprit lesion and non-culprit lesions in the setting of acute myocardial infarction. A scoping literature review was undertaken of the Pubmed database using key words highlighted below.Expert opinion: Prompt and durable revascularization of the infarct-related coronary artery remains the cornerstone of treatment for acute myocardial infarction. Specifically, timely restoration of normal flow and implantation of a DES during the index procedure remains the gold standard; however, deferred treatment and novel devices such as DCB may have an emerging role. Despite much evidence, complete revascularization of non-culprit coronary artery disease in acute myocardial infarction is still the subject of contention.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148857165","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Combining patient history and plasma lipoprotein (a) for improving atherosclerotic cardiovascular disease risk assessment. 结合患者病史和血浆lp(a)改善动脉粥样硬化性心血管疾病的风险评估。

IF 2.5

Expert Review of Cardiovascular Therapy Pub Date : 2026-08-20 DOI: 10.1080/14779072.2026.2718197

Matheus Augusto de Oliveira Amorim, José Moreira Kffuri Filho, Viviane Zorzanelli Rocha

引用次数: 0

Ensuring durable pulmonary vein isolation for atrial fibrillation: prevention of collateral thermal injury and lesion inconsistency. 确保房颤持久肺静脉隔离：预防侧支热损伤和病变不一致。

IF 2.5

Expert Review of Cardiovascular Therapy Pub Date : 2026-08-07 DOI: 10.1080/14779072.2026.2714259

Cristian Martignani, Alberto Spadotto, Maria Carelli, Lorenzo Bartoli, Andrea Angeletti, Igor Diemberger, Giulia Massaro

{"title":"Ensuring durable pulmonary vein isolation for atrial fibrillation: prevention of collateral thermal injury and lesion inconsistency.","authors":"Cristian Martignani, Alberto Spadotto, Maria Carelli, Lorenzo Bartoli, Andrea Angeletti, Igor Diemberger, Giulia Massaro","doi":"10.1080/14779072.2026.2714259","DOIUrl":"10.1080/14779072.2026.2714259","url":null,"abstract":"Introduction: Pulmonary vein isolation (PVI) is the cornerstone of catheter ablation for atrial fibrillation (AF). Despite major technological advances, arrhythmia recurrence remains common because of pulmonary vein reconnection caused by non-durable lesions. Achieving durable PVI requires balancing effective lesion formation with the prevention of collateral injury.Areas covered: This review examines the biophysical determinants of lesion formation, mechanisms responsible for lesion inconsistency, and strategies to improve lesion durability while minimizing collateral injury. The literature was identified through a structured review of major clinical trials, observational studies, mechanistic investigations, and contemporary guideline documents focusing on radiofrequency, cryoballoon, laser balloon, and pulsed field ablation technologies, together with emerging approaches for lesion assessment and procedural optimization.Expert opinion: Durable PVI depends not only on the energy source but also on precise control of catheter-tissue interaction, lesion contiguity, and individualized energy delivery. Pulsed field ablation has substantially improved procedural safety by reducing collateral thermal injury; however, durable lesion formation remains dependent on adequate tissue contact and appropriate energy delivery. Future progress will be driven less by the development of new energy sources than by technologies capable of providing real-time lesion verification and patient-specific ablation strategies.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"1-13"},"PeriodicalIF":2.5,"publicationDate":"2026-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148677658","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Identifying patients at risk of Takotsubo syndrome during cancer treatment: a sex-based cardio-oncology review. 在癌症治疗期间识别有Takotsubo综合征风险的患者：基于性别的心脏肿瘤学综述

IF 2.5

Expert Review of Cardiovascular Therapy Pub Date : 2026-08-05 DOI: 10.1080/14779072.2026.2714263

Nicole Tesoro, Jennifer Marsidi, Jonathan Spaan, Henry Okoroike, Joanne Sutter, Rebecca Jonas, Marie Altenburg, Tochi Okwuosa, Annabelle Santos Volgman

{"title":"Identifying patients at risk of Takotsubo syndrome during cancer treatment: a sex-based cardio-oncology review.","authors":"Nicole Tesoro, Jennifer Marsidi, Jonathan Spaan, Henry Okoroike, Joanne Sutter, Rebecca Jonas, Marie Altenburg, Tochi Okwuosa, Annabelle Santos Volgman","doi":"10.1080/14779072.2026.2714263","DOIUrl":"10.1080/14779072.2026.2714263","url":null,"abstract":"Introduction: Takotsubo syndrome is an acute, transient ventricular dysfunction that frequently mimics acute coronary syndrome. Patients with cancer may be particularly vulnerable because malignancy-related stress and cancer therapies converge with cardiovascular susceptibility.Areas covered: This narrative review examines sex-related susceptibility and acuity, cancer-related stressors, implicated therapy classes, diagnostic differentiation, management, and treatment rechallenge. PubMed/MEDLINE was searched from January 2000 through June 2026 using combinations of terms for Takotsubo syndrome, cancer, cardio-oncology, sex, specific antineoplastic agents, imaging, outcomes, and rechallenge; reference lists of relevant consensus statements and reviews were also screened. Evidence is predominantly derived from registries, retrospective cohorts, case series, and case reports.Expert opinion: Sex should be treated as a risk modifier rather than a stand-alone determinant. A cumulative vulnerability framework integrating patient susceptibility, cancer-related stress burden, and treatment exposure may support earlier recognition and multidisciplinary decisions, but prospective validation and standardized sex-stratified reporting are required.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"1-12"},"PeriodicalIF":2.5,"publicationDate":"2026-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148663754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Suitability of sedative usage in patients undergoing cardiovascular surgery. 心血管手术患者使用镇静剂的适宜性。

IF 2.5

Expert Review of Cardiovascular Therapy Pub Date : 2026-08-01 Epub Date: 2026-07-13 DOI: 10.1080/14779072.2026.2703069

Nathaniel J Martin, Hannah M Brinkman, Sarah Ellis, Christoph G S Nabzdyk, Jamel P Ortoleva, Erica D Wittwer, Jacopo D'Andria Ursoleo, Patrick M Wieruszewski, Fabrizio Monaco

{"title":"Suitability of sedative usage in patients undergoing cardiovascular surgery.","authors":"Nathaniel J Martin, Hannah M Brinkman, Sarah Ellis, Christoph G S Nabzdyk, Jamel P Ortoleva, Erica D Wittwer, Jacopo D'Andria Ursoleo, Patrick M Wieruszewski, Fabrizio Monaco","doi":"10.1080/14779072.2026.2703069","DOIUrl":"10.1080/14779072.2026.2703069","url":null,"abstract":"Introduction: The provision of optimal anesthesia care is essential to the safe conduct of cardiac surgery. Nevertheless, evidence regarding ideal choices for anesthetic induction and maintenance remain conflicting. Individualized regimens balancing the patient's cardiac pathology and the expected hemodynamic perturbations from the anesthetics are likely optimal, underscoring the rationale for this review of contemporary anesthetic strategies in cardiac surgery.Areas covered: Descriptions of cardiac surgery trends and advancements that necessitate concomitant anesthesia, including the challenges with the provision of anesthesia in these patients were introduced. Induction and maintenance anesthesia considerations are discussed next, along with individual medication-specific commentary on volatile anesthetics, propofol, benzodiazepines, barbiturates, ketamine, etomidate, opioids, dexmedetomidine, and remimazolam. PubMed/MEDLINE, EMBASE, and Google Scholar were searched without date restriction through April 2026.Expert opinion: An optimal blanket anesthetic strategy for patients undergoing cardiac surgery remains elusive. Thoughtful combinations of multiple agents considering the patient's physiology, anticipated hemodynamic perturbations, and type and length of surgery are likely to continue to dominate practice. Novel agents, like remimazolam, may prove especially fruitful for patients given their unique properties, but more evidence is needed to prove impact on patient outcomes for this, and other agents in combination.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"715-727"},"PeriodicalIF":2.5,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148419918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prioritizing psychological distress reduction during pregnancy for improved cardiovascular health. 优先减少怀孕期间的心理困扰，以改善心血管健康。

IF 2.5

Expert Review of Cardiovascular Therapy Pub Date : 2026-08-01 Epub Date: 2026-07-27 DOI: 10.1080/14779072.2026.2707424

Talha Khalid, Muhammad Ramish Irfan, Jeffrey Shi Kai Chan, Danish Iltaf Satti

引用次数: 0

Early changes in renal function do not appear to mediate cardiovascular risk with dapagliflozin plus semaglutide: a real-world observational hypothesis-generating cohort study. 肾功能的早期改变似乎不会介导达格列净加西马鲁肽的心血管风险：一项真实世界的观察性假设生成队列研究。

IF 2.5

Expert Review of Cardiovascular Therapy Pub Date : 2026-08-01 Epub Date: 2026-08-02 DOI: 10.1080/14779072.2026.2713476

Muneera O AlTaweel, Saleh Al Makhloof, Ahmad K AlKhayyal, Jawaher Alrashada, Munirah AlOhaymid, Abdullah Alshahrani, Abdullatif W Alarfaj, Turki A Alqarni, Ghusoon Al Moaibed, Noor M Altharman

{"title":"Early changes in renal function do not appear to mediate cardiovascular risk with dapagliflozin plus semaglutide: a real-world observational hypothesis-generating cohort study.","authors":"Muneera O AlTaweel, Saleh Al Makhloof, Ahmad K AlKhayyal, Jawaher Alrashada, Munirah AlOhaymid, Abdullah Alshahrani, Abdullatif W Alarfaj, Turki A Alqarni, Ghusoon Al Moaibed, Noor M Altharman","doi":"10.1080/14779072.2026.2713476","DOIUrl":"10.1080/14779072.2026.2713476","url":null,"abstract":"Background: Cardiovascular-kidney-metabolic (CKM) syndrome links heart failure (HF), myocardial infarction (MI), kidney disease, diabetes, and obesity. SGLT2 inhibitors and GLP-1 receptor agonists improve cardiovascular and renal outcomes, but mechanisms underlying combination therapy remain uncertain. We assessed whether early changes in estimated glomerular filtration rate (ΔeGFR) mediate the association between dapagliflozin plus semaglutide and HF/MI-related outcomes.Research design and methods: We conducted a retrospective cohort study of 376 adults prescribed dapagliflozin, with or without semaglutide, at a Saudi tertiary hospital (2020-2024). Inverse probability of treatment weighting and causal mediation analysis evaluated whether ΔeGFR mediated treatment-outcome associations during 90-365days of follow-up.Results: Combination therapy was not associated with a statistically significant difference in recorded HF/MI-related clinical status (adjusted RR 0.787; 95% bootstrap CI 0.320-1.813; p = 0.516). ΔeGFR showed minimal mediation (indirect RR 1.013; 95% CI 0.901-1.165). IPTW analyses yielded similar neutral findings (composite RR 1.12; 95% CI 0.47-2.66).Conclusions: Early ΔeGFR showed little evidence of mediating HF/MI-related risk differences between combination therapy and dapagliflozin alone. Because outcomes were not independently adjudicated, these secondary findings are exploratory. Larger prospective studies are needed.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"743-750"},"PeriodicalIF":2.5,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148629824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Contemporary role of drug-coated balloons for in-stent restenosis: a critical appraisal of available evidence. 药物包被球囊在支架内再狭窄中的当代作用：对现有证据的关键评价。

IF 2.5

Expert Review of Cardiovascular Therapy Pub Date : 2026-08-01 Epub Date: 2026-07-14 DOI: 10.1080/14779072.2026.2703064

Andrea Milzi, Marco Frazzetto, Antonio Landi

引用次数: 0

Molecular and imaging biomarkers in myocardial ischemia/reperfusion injury: from pathogenetic mechanisms to therapeutic targeting. 心肌缺血/再灌注损伤的分子和成像生物标志物：从发病机制到治疗靶向。

IF 2.5

Expert Review of Cardiovascular Therapy Pub Date : 2026-08-01 Epub Date: 2026-07-13 DOI: 10.1080/14779072.2026.2703072

Athina Nasoufidou, Marios G Bantidos, Christos Kofos, Nikolaos Stalikas, Andreas Mitsis, Panagiotis Stachteas, Paschalis Karakasis, Maria Fasoula, Barbara Fyntanidou, George Kassimis, Nikolaos Fragakis, Efstratios Karagiannidis

{"title":"Molecular and imaging biomarkers in myocardial ischemia/reperfusion injury: from pathogenetic mechanisms to therapeutic targeting.","authors":"Athina Nasoufidou, Marios G Bantidos, Christos Kofos, Nikolaos Stalikas, Andreas Mitsis, Panagiotis Stachteas, Paschalis Karakasis, Maria Fasoula, Barbara Fyntanidou, George Kassimis, Nikolaos Fragakis, Efstratios Karagiannidis","doi":"10.1080/14779072.2026.2703072","DOIUrl":"10.1080/14779072.2026.2703072","url":null,"abstract":"Introduction: Ischemic heart disease remains a leading cause of morbidity and mortality worldwide despite advances in diagnosis, revascularization, and risk-factor control. Myocardial ischemia/reperfusion (I/R) injury (MIRI) is a multiphase process evolving over minutes to weeks, contributing to infarct expansion, microvascular obstruction, intramyocardial hemorrhage, and adverse ventricular remodeling. High-sensitivity cardiac troponins remain central to diagnosing myocardial necrosis but provide limited mechanistic insight into upstream MIRI processes.Areas covered: For this review, PubMed/MEDLINE and Scopus were searched from inception to May 2026. Established and emerging biomarkers are examined across the I/R continuum, including tissue-derived markers, inflammatory and oxidative-stress mediators, endothelial and neurohormonal biomarkers, remodeling-related proteins, non-coding RNAs, cell-free DNA, extracellular vesicles, metabolomic and proteomic signatures, and multi-omics platforms. Cardiac magnetic resonance and positron emission tomography are also analyzed for tissue characterization and complication detection.Expert opinion: The most realistic role for MIRI biomarkers is selective post-reperfusion phenotyping, as high-sensitivity cardiac troponins will remain the diagnostic anchor in acute myocardial infarction. Their initial clinical value is likely prognostic, refining risk stratification and follow-up intensity. Translation will require standardized assays, harmonized sampling, evidence of incremental value, and prospective demonstration that biomarker-guided decisions improve outcomes, resource allocation, cost-effectiveness, and trial efficiency.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"697-713"},"PeriodicalIF":2.5,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148419968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0